reports
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosi...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA. “We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development of a novel laboratory-based autoantibody blood test that can provide a definitive diagnosis of aPAP,” said M...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 21, 2024, Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 125,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of the Company’s common stock. These equity awards were granted under the Savara...
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Prov...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update. “We look forward to reporting IMPALA-2 top line results at the end of the second quarter and, assuming positive data, anticipate filing the BLA in the first half of 2025,” said Matt Pauls, Chair and CEO, Savara. “2023 was a year of strong execution that included the on-time, over-enrollment of the Phase 3 IMPALA-2 trial and an an...
Savara to Present at the Barclays 26th Annual Global Healthcare Confer...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocy...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On January 31, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 70,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 30,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2...
Savara to Present at Two Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Corporate Presentation Virtual Conference A webcast of each presentation will be available through the Inve...
Savara Inc: 3 directors
Three Directors at Savara Inc sold after exercising options/gave away/sold 206,843 shares at between 0.000USD and 4.713USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can be used by physicians in the U.S. to obtain a definitive diagnosis of aPAP, a rare autoimmune lung disease mediated by autoantibodies targeting GM-CSF. Autoimmune PAP accounts for approximately 90% of all patients with PAP and has an estimated diagnosed prevalence of seven cases per million in the U.S. and similar or higher prevalence reported elsewhere in the world. The aPAP ...
Savara Added to the NASDAQ Biotechnology Index
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified ca...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On December 11, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 110,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 80,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc....
Savara to Present at the Piper Sandler 35th Annual Healthcare Conferen...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granul...
Savara Reports Third Quarter Financial Results and Provides Business U...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update. “We remain on track to report top line data from the pivotal, Phase 3 IMPALA-2 trial by the end of the second quarter 2024,” said Matt Pauls, Chair and CEO, Savara. “In parallel, we are working to provide pulmonologists in the U.S. and Europe with a simple, accurate, no-cost, laboratory-based antibody blood test for aPAP. This antibody test is...
Savara to Present at the Jefferies London Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm GMT/7:00am EST. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On October 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 50,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 30,000 shares of the Company’s common stock. These equity aw...
Savara to Present at the H.C. Wainwright 25th Annual Global Investment...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast of the presentation will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macroph...
- Jonathan Moreland
LPSN LIVEPERSON INC.
INTC INTEL CORPORATION
HRTX HERON THERAPEUTICS INC
GGG GRACO INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CROX CROCS INC.
AQMS AQUA METALS INC
ACTG ACACIA RESEARCH CORP. - ACACIA TECHNOLOGIES
ADC AGREE REALTY CORPORATION
CULP CULP INC.
CNA CNA FINANCIAL CORPORATION
NTIC NORTHERN TECHNOLOGIES INTERNATIONAL
FBK FB FINANCIAL CORPORATION
XOM EXXON MOBIL CORPORATION
SNAP SNAP INC. CLASS A
SVRA SAVARA
GNTY GUARANTY BANCSHARES INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
VBIV VBI VACCINES INC/BC
TDW TIDEWATER INC
ILPT INDUSTRIAL LOGISTICS
ZM ZOOM VIDEO COMMUNICATIONS
PAYS INC.
QMCO PAYSIGN INC
ENX QUANTUM CORP /DE/
ZI EATON VANCE NEW YORK MUNICIPAL BOND FUND
AWH ZOOMINFO TECHNOLOGIES INC.
RILY ASPIRA WOMEN'S HEALTH INC.
INZY B. RILEY FINANCIAL
HPK INOZYME PHARMA
PVBC HIGHPEAK ENERGY INC (A)
SHYF PROVIDENT BANCORP INC
NRGX THE SHYFT GROUP INC
CYTH PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
YELL CYCLO THERAPEUTICS
TCS YELLOW CORPORATION
RXST CONTAINER STORE GROUP
CMU INC.
JANX RXSIGHT INC
TTNP MFS HIGH YIELD MUNICIPAL TRUST
EMO JANUX THERAPEUTICS INC
MTEM TITAN PHARMACEUTICALS INC
ABOS CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
STCN MOLECULAR TEMPLATES
INC.
ACUMEN PHARMACEUTICALS
INC.
STEEL CONNECT INC
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On August 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 150,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(...
- Jonathan Moreland
PFSW PFSWEB INC
MPAA MOTORCAR PARTS OF AMERICA INC.
CVGW CALAVO GROWERS INC.
AQMS AQUA METALS INC
ACTG ACACIA RESEARCH CORP. - ACACIA TECHNOLOGIES
CULP CULP INC.
ENPH ENPHASE ENERGY INC.
TTC TORO COMPANY
GHC GRAHAM HOLDINGS CO.
SCWX SECUREWORKS
CDZI CADIZ INC.
SVRA SAVARA
PMM PUTNAM MANAGED MUNICIPAL INCOME TRUST
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
SMBC SOUTHERN MISSOURI BANCORP INC.
PMO PUTNAM MUNICIPAL OPPORTUNITIES TRUST
VBIV VBI VACCINES INC/BC
CVLY CODORUS VALLEY BANCORP INC.
OXSQ OXFORD SQUARE CAPITAL
SMAR SMARTSHEET
EVLO EVELO BIOSCIENCES
NHS NEUBERGER BERMAN HIGH YIELD ST
LARK LANDMARK BANCORP INC.
ZM ZOOM VIDEO COMMUNICATIONS
BW INC.
QMCO BABCOCK & WILCOX ENTERPRISES
BDTX QUANTUM CORP /DE/
ENX BLACK DIAMOND THERAPEUTICS
EPSN INC.
ZI EATON VANCE NEW YORK MUNICIPAL BOND FUND
PASG EPSILON ENERGY LIMITED
GRIL ZOOMINFO TECHNOLOGIES INC.
ACET PASSAGE BIO
ALVR INC.
HPK MUSCLE MAKER
MAX ADICET BIO INC
CLNN ALLOVIR
NRGX HIGHPEAK ENERGY INC (A)
RMBL MEDIAALPHA
JANX INC.
TTNP CLENE INC
EFSH PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
MTEM RUMBLEON INC
OKE JANUX THERAPEUTICS INC
TITAN PHARMACEUTICALS INC
1847 HLDGS LLC
MOLECULAR TEMPLATES
INC.
ONEOK
INC.
- Jonathan Moreland
Savara Announces Pricing of $80 Million Underwritten Offering of Commo...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share and, in lieu of common stock to certain investors that so choose, 5,666,667 pre-funded warrants to purchase common stock at a price of $2.999 per pre-funded warrant, in each case before deducting underwriting discounts and commissions, for total gross proceeds of approximately $80 million. All of the securities to be sold in the offering a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.